Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization

NCT00317512 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Angina Pectoris
Unstable Angina
Myocardial Infarction

Interventions

PROCEDURE: Percutaneous Coronary Revascularization
DRUG: Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)
DRUG: Voluven

Sponsor

Biopure Corporation